Extract of Platycodon grandiflorum Prevents Doxorubicin-induced Cardiotoxicity in Breast Cancer

Doxorubicin (Dox) is a first-line chemotherapeutic agent applied in cancer treatment. Its long-term anticancer efficacy is restricted mainly due to its subsequent cardiotoxicity for patients. Platycodon grandiflorum (PG), an important traditional Chinese herb, has been reported to eliminate phlegm, relieve cough, and reduce inflammatory diseases. Previous clinical studies found that PG has cardioprotective effects for early breast cancer patients who received Dox-based chemotherapy. However, the cellular and molecular mechanisms underlying PG-mediated cardiotoxic rescue remain elusive. This study aimed to explore the protective role and potential molecular mechanisms of PG on Dox-induced cardiac dysfunction in a mouse model of breast cancer. PG significantly alleviated myocardial damage and prevented cardiomyocyte apoptosis induced by Dox. The expression levels of cytochrome C and cleaved caspase-3 significantly decreased, and the levels of Bcl-XL and B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein increased following PG treatment. Furthermore, PG remarkably enhanced the antimetastatic efficacy (versus the Dox group) by regulating the balance of matrix metalloproteinases/tissue inhibitors of metalloproteinases.

Automated summary

This study aimed to explore the protective role and potential molecular mechanisms of the Chinese herb Platycodon grandiflorum (PG) on Doxorubicin-induced cardiac dysfunction in a mouse model of breast cancer. The results showed that PG significantly alleviated myocardial damage and prevented cardiomyocyte apoptosis induced by Doxorubicin. PG treatment led to decreased expression levels of cytochrome C and cleaved caspase-3, and increased levels of Bcl-XL, B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein. Furthermore, PG remarkably enhanced the antimetastatic efficacy by regulating the balance of matrix metalloproteinases/tissue inhibitors of metalloproteinases.